Novo Nordisk Shares Tumble as Obesity Drug Fails to Beat Eli Lilly
Novo Nordisk shares plummeted 16% on Monday after its experimental obesity treatment, CagriSema, failed to outperform Eli Lilly’s rival drug Zepbound in a critical head-to-head clinical trial. The Danish pharmaceutical giant reported that CagriSema missed its primary goal of demonstrating noninferior weight loss, dealing a significant blow to the company's efforts to reclaim dominance in the global weight-loss market.
In the late-stage study, patients treated with CagriSema achieved a weight loss of 23% over 84 weeks. However, those receiving Eli Lilly’s tirzepatide—marketed as Zepbound for obesity and Mounjaro for diabetes—recorded a superior weight reduction of 25.5%. This failure to match the efficacy of a drug already on the market underscores the intensifying competition in a sector Novo Nordisk helped pioneer.
Market Pressure and Strategic Setbacks
The trial results triggered a sharp sell-off, extending a punishing year for the drugmaker in which its shares have lost more than half their value. The setback comes at a sensitive time for the company, which is navigating a broader leadership reshuffle and recent job cuts following warnings of weaker-than-expected financial results. Analysts had previously signaled that CagriSema’s commercial viability hinged on its ability to at least match the performance profile of Eli Lilly’s offerings.
CagriSema is a combination therapy that pairs semaglutide, the active ingredient in Ozempic and Wegovy, with an experimental compound called cagrilintide. Despite the disappointing trial outcome, Novo Nordisk confirmed it submitted an application to the U.S. Food and Drug Administration in December, with a regulatory decision anticipated by late 2026. The company stated it is currently exploring the drug's potential through additional trials, including the testing of higher-dose combinations to maximize weight-loss results.
Comments (0)
No comments yet. Be the first!